The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
Open Access
- 30 April 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 6 (1), 7002
- https://doi.org/10.1038/ncomms8002
Abstract
The development of molecularly targeted anticancer agents relies on large panels of tumour-specific preclinical models closely recapitulating the molecular heterogeneity observed in patients. Here we describe the mutational and gene expression analyses of 151 colorectal cancer (CRC) cell lines. We find that the whole spectrum of CRC molecular and transcriptional subtypes, previously defined in patients, is represented in this cell line compendium. Transcriptional outlier analysis identifies RAS/BRAF wild-type cells, resistant to EGFR blockade, functionally and pharmacologically addicted to kinase genes including ALK, FGFR2, NTRK1/2 and RET. The same genes are present as expression outliers in CRC patient samples. Genomic rearrangements (translocations) involving the ALK and NTRK1 genes are associated with the overexpression of the corresponding proteins in CRC specimens. The approach described here can be used to pinpoint CRCs with exquisite dependencies to individual kinases for which clinically approved drugs are already available.Keywords
This publication has 46 references indexed in Scilit:
- An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small MoleculesCell, 2013
- Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± CetuximabClinical Cancer Research, 2013
- Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancerThe Journal of Pathology, 2013
- Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic ValuePLoS Medicine, 2013
- Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesionsNature Medicine, 2013
- Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon CancerJNCI Journal of the National Cancer Institute, 2012
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- Systematic identification of genomic markers of drug sensitivity in cancer cellsNature, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Integrative Analysis of Proteomic Signatures, Mutations, and Drug Responsiveness in the NCI 60 Cancer Cell Line SetMolecular Cancer Therapeutics, 2010